FREEHOLD, NJ, Sept. 29, 2022 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. AVCOa leading global developer of innovative cell-based technologies and therapeutics, today released an update on the company’s intellectual property portfolio featuring its QTY protein code technology.

The Company has received a Notice of Acceptance from the United States Patent and Trademark Office (USPTO) with respect to its QTY water-soluble receptor protein fusion platform. The patent was jointly awarded with Dr. Shuguang Zhang of Massachusetts Institute of Technology (MIT) and includes seven claims related to the technology.

The company also filed a new patent application with the USPTO related to its QTY glucose transporter technology. This patent application was also filed jointly with Dr. Shuguang Zhang submitted by MIT. QTY glucose transporters are deregulated in many tumor types and are potentially important targets for cancer therapy.

The “QTY code” is a breakthrough technology that can convert difficult-to-handle water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their potential use in many clinical applications, including drug development.

Avalon’s proprietary AVA-Trap™ technology uses artificial intelligence (AI) enhanced QTY code technology to convert receptor molecules into antibody-like decoy receptors capable of scavenging cytokines and chemokines secreted during pathological conditions such as COVID-19 19 are overproduced. 19 and cancer metastases.

“We continue to strengthen our IP portfolio as we believe our novel QTY code protein design technology offers great potential for biotechnology applications and could lead to significant clinical advances in cellular immunotherapy and immuno-oncology,” said David Jin, MD, Ph.D., President and Chief Executive Officer of Avalon. “Our AI-enhanced protein design QTY code technology, developed jointly with Dr. Zhang of MIT is a novel platform that produces water-soluble proteins for a broad spectrum…